France Requests Lancet To Review Study On HCQ

Hydroxychloroquine, the anti-malarial drug has been mired in a fresh set of controversies as a paper published in the journal Lancet that the drug is leading to an increase in arrhythmia in patients in 671 hospitals has been questioned for the data's veracity. 

The company that provided the data, Surgisphere is not willing to divulge any further details about hospitals or participants which has raised eyebrows in the scientific community. 

French Health Minister Olivier Veran has written to Lancet to review this data as France discontinued its trials on HCQ. A French study was the first one to highlight the merits of the drug.